Pathogenesis, classification, and treatment of myelodysplastic syndromes (MDS).
Myelodysplastic syndromes (MDS) comprise a heterogeneous group of clonal myeloid disorders characterized by morphologic dysplasia in one or more cell lineages. Dysplasia in MDS is associated with insufficient production of blood cells and consecutive cytopenia(s). The natural course and prognosis of MDS vary among patients and depend on genetic defects that occur during clonal evolution. In a significant group of patients (roughly 30%) progression to secondary leukemia is observed. These patients appear to have a grave prognosis. The treatment of patients with MDS has to be adjusted to the individual situation and age in each case. In many patients, control of blast cell production by palliative cytoreduction, continuous support with red blood cells, as well as other supportive measures, seem appropriate. In other patients, however, curative therapy (chemotherapy, stem cell transplantation) should be considered. The final decision to offer curative therapy must be based on many different factors including age and the overall situation of the patient. Recently established scoring systems aimed at predicting survival and evolution of leukemia in MDS may be helpful in this regard.
D000328:Adult; D000367:Age Factors; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001856:Bone Marrow Examination; D016026:Bone Marrow Transplantation; D002986:Clinical Trials as Topic; D003937:Diagnosis, Differential; D018572:Disease-Free Survival; D006801:Humans; D007621:Karyotyping; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000145:classification / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology / Q000235:genetics / Q000401:mortality / Q000628:therapy; D010166:Palliative Care; D018579:Patient Selection; D011379:Prognosis; D012307:Risk Factors; D033581:Stem Cell Transplantation; D013997:Time Factors; D014944:World Health Organization
D000970:Antineoplastic Agents